Payment overview · 2025
General Payments
$1,117.64
46 reported records · 12 companies
Healthcare provider profile · identity verified
Tien Thi Kim Do
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · WESTMINSTER, CA · NPI 1508348632
Verified facts
What the public records show
CMS Open Payments records show Tien Thi Kim Do received $1,117.64 in general payments during 2025 across 46 reported records.
Aimmune Therapeutics, Inc. accounted for 16.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess, Ozempic, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $178.94 | 16.0% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $171.96 | 15.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $134.66 | 12.1% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $114.71 | 10.3% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $104.55 | 9.3% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $99.04 | 8.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.99 | 7.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $86.15 | 7.7% | 4 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $66.50 | 6.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.57 | 3.4% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $21.97 | 2.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.60 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,117.64 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $209.93 | 8 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $178.94 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $157.59 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $114.71 | 5 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $99.04 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $86.15 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $85.73 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $71.36 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $69.53 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $60.47 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.89 | 2 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $46.13 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $39.10 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.28 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.28 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| QSYMIA Normalized: qsymia |
Drug | VIVUS LLC | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 93 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 141 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 34 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | 16 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
93 | 28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
141 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
141 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 459 | 252 |
| Amlodipine Besylate | Amlodipine Besylate | 322 | 177 |
| Losartan Potassium | Losartan Potassium | 320 | 177 |
| Metformin Hcl | Metformin Hcl | 212 | 106 |
| Jardiance | Empagliflozin | 141 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 72 |
| Vascepa | Icosapent Ethyl | 113 | 47 |
| Famotidine | Famotidine | 103 | 66 |
| Finasteride | Finasteride | 102 | 51 |
| Farxiga | Dapagliflozin Propanediol | 93 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 91 | 68 |
| Azithromycin | Azithromycin | 88 | 75 |
| Gabapentin | Gabapentin | 88 | 49 |
| Tradjenta | Linagliptin | 86 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 74 | 43 |
| Omeprazole | Omeprazole | 70 | 35 |
| Atenolol | Atenolol | 69 | 36 |
| Lovastatin | Lovastatin | 68 | 34 |
| Amoxicillin | Amoxicillin | 67 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 32 |
| Icosapent Ethyl | Icosapent Ethyl | 54 | 18 |
| Januvia | Sitagliptin Phosphate | 54 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 30 |
| Tramadol Hcl | Tramadol Hcl | 49 | 23 |
| Prednisone | Prednisone | 48 | 47 |
| Baclofen | Baclofen | 43 | 25 |
| Celecoxib | Celecoxib | 42 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 23 |
| Glipizide Er | Glipizide | 40 | 19 |
| Lisinopril | Lisinopril | 40 | 16 |
| Clonidine Hcl | Clonidine Hcl | 37 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 19 |
| Trazodone Hcl | Trazodone Hcl | 37 | 20 |
| Allopurinol | Allopurinol | 36 | 17 |
| Linzess | Linaclotide | 34 | 16 |
| Alendronate Sodium | Alendronate Sodium | 33 | 18 |
| Benazepril Hcl | Benazepril Hcl | 32 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 32 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | 16 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 31 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 31 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 16 |
| Hydrocortisone | Hydrocortisone | 31 | 20 |
| Ibuprofen | Ibuprofen | 31 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | 18 |
| Meloxicam | Meloxicam | 30 | 19 |
| Donepezil Hcl | Donepezil Hcl | 29 | 21 |
| Furosemide | Furosemide | 29 | 16 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 28 | 15 |
| Cyclosporine | Cyclosporine | 28 | 17 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | 24 |
| Loperamide | Loperamide Hcl | 27 | 24 |
| Meclizine Hcl | Meclizine Hcl | 25 | 25 |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 24 | suppressed |
| Carvedilol | Carvedilol | 23 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 18 |
| Mupirocin | Mupirocin | 23 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 20 |
| Restasis | Cyclosporine | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 21 | 14 |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Felodipine Er | Felodipine | 20 | suppressed |
| Naproxen | Naproxen | 20 | 17 |
| Cephalexin | Cephalexin | 19 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | 12 |
| Eliquis | Apixaban | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | 11 |
| Sucralfate | Sucralfate | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Triazolam | Triazolam | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 14 |
| Prolia | Denosumab | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,117.64 · 46 records | Aimmune Therapeutics, Inc. | AIRSUPRA, AREXVY, BREZTRI, CREON, Cologuard Collection Kit, DUPIXENT, EVENITY, FARXIGA, JARDIANCE, LINZESS, MOUNJARO, OTEZLA, Ozempic, PANCREAZE, QSYMIA, REPATHA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, ZENPEP, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error